Form 8-K - Current report:
SEC Accession No. 0001193125-24-284671
Filing Date
2024-12-26
Accepted
2024-12-26 07:30:30
Documents
17
Period of Report
2024-12-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d861236d8k.htm   iXBRL 8-K 32671
2 EX-4.1 d861236dex41.htm EX-4.1 69567
3 EX-5.1 d861236dex51.htm EX-5.1 9341
4 EX-10.1 d861236dex101.htm EX-10.1 121811
8 GRAPHIC g861236g1225091710379.jpg GRAPHIC 2804
  Complete submission text file 0001193125-24-284671.txt   422420

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA tcrx-20241226.xsd EX-101.SCH 2857
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrx-20241226_lab.xml EX-101.LAB 17979
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrx-20241226_pre.xml EX-101.PRE 11263
19 EXTRACTED XBRL INSTANCE DOCUMENT d861236d8k_htm.xml XML 3637
Mailing Address 880 WINTER STREET WALTHAM MA 02451
Business Address 880 WINTER STREET WALTHAM MA 02451 857-399-9500
TScan Therapeutics, Inc. (Filer) CIK: 0001783328 (see all company filings)

EIN.: 825282075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40603 | Film No.: 241576188
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)